Healthcare >> CEO Interviews >> April 1, 1998
FRANK A. HOLLER, President & CEO of Xenon Genetics, is a well-known
biotechnology executive. Prior to joining Xenon in February 1999, Mr.
Holler was President & CEO and a co-Founder of ID Biomedical as well as
a founding Director of Angiotech Pharmaceuticals. Mr. Holler is also
Chairman of BIRC Corporation, a Vancouver-based government-funded
venture capital company, a Director of analytical services company
CanTest, and a Director of Cromedica Prime, a Phase I clinical trials
company located in British Columbia. Prior to working in biotechnology
and health care, Mr. Holler was an investment banker with Merrill Lynch
Canada and CIBC World Markets. He holds a BA in Economics and an MBA in
Business Administration from the University of British Columbia. Profile
rundown of what you see as the mission for ID Biomedical?
Mr. Holler: Our company is in two areas of business: rapid
